We are live on ! Find out more
KYTH

KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH

Delisted

KYTH was delisted on the 30th of September, 2015.

83 hedge funds and large institutions have $453M invested in KYTHERA BIOPHARMACEUTICALS, INC COM in 2013 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 4

143% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 14

96% more capital invested

Capital invested by funds: $231M → $453M (+$222M)

28% more funds holding

Funds holding: 6583 (+18)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
83
Holders Change
+18
Holders Change %
+27.69%
% of All Funds
2.69%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
22
Increased
34
Reduced
14
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
51
Citadel Advisors
Florida
$473K +$310K +10,350 New
SKK
52
Shepherd Kaplan Krochuk
Massachusetts
$460K
HHC
53
Hutchin Hill Capital
New York
$456K
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$418K +$30 +1 +0%
Swiss National Bank
55
Swiss National Bank
Switzerland
$416K +$156K +5,200 +133%
State Board of Administration of Florida Retirement System
56
State Board of Administration of Florida Retirement System
Florida
$415K
MLICM
57
Metropolitan Life Insurance Company (MetLife)
New York
$397K
VOYA Investment Management
58
VOYA Investment Management
Georgia
$388K
ARTA
59
A.R.T. Advisors
New York
$381K +$250K +8,361 New
AIG
60
American International Group
New York
$312K +$100K +3,350 +96%
Mackenzie Financial
61
Mackenzie Financial
Ontario, Canada
$306K +$219K +7,338 New
ProShare Advisors
62
ProShare Advisors
Maryland
$294K +$193K +6,440 New
FMT
63
First Mercantile Trust
Tennessee
$242K +$159K +5,300 New
EIM
64
Essex Investment Management
Massachusetts
$230K -$92K -3,075 -38%
BA
65
BlackRock Advisors
Delaware
$213K +$718 +24 +0.5%
Morgan Stanley
66
Morgan Stanley
New York
$211K +$139K +4,632 New
SEIA
67
Signature Estate & Investment Advisors
California
$200K +$131K +4,388 New
SG Americas Securities
68
SG Americas Securities
New York
$130K +$85.2K +2,849 New
PA
69
Perceptive Advisors
New York
$126K +$82.7K +2,765 New
Wells Fargo
70
Wells Fargo
California
$96K +$63K +2,105 New
PAM
71
Panagora Asset Management
Massachusetts
$62K
Teacher Retirement System of Texas
72
Teacher Retirement System of Texas
Texas
$59K +$18K +601 +87%
TRCT
73
Tower Research Capital (TRC)
New York
$51K -$37.2K -1,244 -53%
California Public Employees Retirement System
74
California Public Employees Retirement System
California
$18K +$5.98K +200 +100%
Barclays
75
Barclays
United Kingdom
$17K -$4.4K -147 -28%

KYTH Hedge Fund Activity: Q3 2013 in Review

83 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) for Q3 2013, worth a combined $453M — up 96% from $231M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new KYTH positions and 4 closed out — a net gain of 18 holders — while 34 added to existing stakes and 14 trimmed.

The largest buyer was Waddell & Reed Financial, opening a new position worth an estimated $12.7M. The largest seller was PFM Health Sciences, cutting an estimated $10.4M.

  • 83 institutional investors held KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) as of Q3 2013, up from 65 in Q2 2013.
  • Funds reported $453M of KYTHERA BIOPHARMACEUTICALS, INC COM stock for Q3 2013, up 96% quarter-over-quarter.
  • 22 funds opened new KYTHERA BIOPHARMACEUTICALS, INC COM positions in Q3 2013 and 4 closed out, a net change of +18 holders.
  • The largest KYTHERA BIOPHARMACEUTICALS, INC COM buyer in Q3 2013 was Waddell & Reed Financial, an estimated $12.7M added.
  • The largest KYTHERA BIOPHARMACEUTICALS, INC COM seller in Q3 2013 was PFM Health Sciences, an estimated $10.4M sold.

Based on aggregated 13F filings for Q3 2013.